Long‐term follow‐up of patients with intermediate‐risk neuroblastoma treated with response‐ and biology‐based therapy: A report from the Children's Oncology Group study ANBL0531

Ähnliche Einträge

• Outcomes of patients with intermediate‐risk neuroblastoma presenting with motor deficits relating to intraspinal tumor extension: A report from the Children's Oncology Group study ANBL0531
  von: Julie Voeller, et al.
  Veröffentlicht: (2024)
• A pilot study of chemoimmunotherapy in the postconsolidation setting for high‐risk neuroblastoma (ANBL19P1): A report from the Children’s Oncology Group
  von: Ami V. Desai, et al.
  Veröffentlicht: (2026)
• Late cognitive and adaptive outcomes of patients with neuroblastoma‐associated opsoclonus‐myoclonus‐ataxia‐syndrome: A report from the Children's Oncology Group
  von: Prerna Kumar, et al.
  Veröffentlicht: (2024)
• Enrollment on upfront high‐risk neuroblastoma trials by race, ethnicity, and poverty status: A report from the Children's Oncology Group
  von: Puja J. Umaretiya, et al.
  Veröffentlicht: (2024)
• Long‐Term Outcome of Young Infants With Suspected Neuroblastoma following Observation as Primary Therapy: A Report From the Children's Oncology Group
  von: Hetal Dholaria, et al.
  Veröffentlicht: (2025)